Skip to main content
Premium Trial:

Request an Annual Quote

Pronota Lands $2.7M Grant From Flanders Gov’t for Biomarker Discovery, Validation Platform

NEW YORK (GenomeWeb News) — Pronota has won a €1.9 million ($2.7 million) grant from the Flanders government to further develop its diagnostic and pharmacodiagnostic protein biomarker-discovery and -validation platform, the Belgian company said today.
 
Pronota said the grant, which is being awarded through IWT-Flanders, will be used to expand the development of Pronota's first-generation biomarker-discovery platform by building on its capability to identify low-abundant serum protein biomarkers.
 
The company said it will use its low-abundant serum protein biomarkers to develop the new discovery platform, which it will couple with a “novel validation platform.”
 
Taken together, the integrated platforms will allow researchers to “simultaneously assess the levels of a significant number of candidate biomarkers in large patient populations without the upfront requirement to generate antibodies and develop immunoassays.”
 
Funds left over from the primary programs will be used to support “one of Pronota’s internal biomarker-discovery programs,” the company said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.